Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crotedumab (REGN1193) in Type 2 Diabetes
NCT02284425Phase 1Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2014
- Primary completion
- Dec 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of crotedumab in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Incidence and severity of treatment emergent adverse events. Started Oct 2014; status: terminated.
02
Drugs
crotedumab
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02284425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02284425.